Bradford Wood, MD

BA, University of Virginia
MD, University of Virginia

Dr. Wood earned undergraduate and graduate degrees from the University of Virginia, internship in internal medicine, and residency at Georgetown University in Radiology and IR. He was on staff at Massachusetts General Hospital at Harvard after fellowships there in Abdominal Imaging and Intervention and Vascular and Interventional Radiology.

He is a Fellow of the Society of Interventional Radiology and was Acting Co-Director of Radiology in the late 2000’s.

He holds appointments in the NIH Clinical Center, the National Cancer Institute, Urological Oncology Branch, and as Acting Clinical Director of the NIBIB Center for Biomedical Engineering Technology Acceleration.

He has received the NIH Director's Awards, NIH Clinical Center Director's Awards, NIH CC CEO Awards, NIH Bench to Bedside Awards, NIH OD Honor Award, NCI Research Highlights Award, and has co-authored > 650 peer-reviewed papers (H-Index = 112), > 50 patents, and several books. He was the primary inventor of fusion biopsy and fusion ablation. First in human successes include RFA for kidney cancer, pheochromocytoma, and adrenal cancer; fusion biopsy and ablation for cancer; image-able drug-eluting beads for TACE; and ablation or embolization plus checkpoint inhibition for immunomodulation in HCC (with Tim Greten).

His success is on the shoulders of a stellar, diverse, and fun multi-disciplinary team.

Research Topics

Dr. Wood is Chief of IR and founding Director of the NIH Center for Interventional Oncology ((NIH Center for Interventional Oncology) that develops and translates novel devices, software, and navigation approaches for cancer patients within a multi-disciplinary framework. Biomedical engineering is applied to unmet clinical needs via novel local and regional minimally-invasive image-guided therapies.

His team's achievements include helping to pioneer technologies from concept to bench to patient, including “first-in-human” for device/drug combinations, prostate cancer MRI/TRUS fusion biopsy and ablation, image-able iodinated drug eluting beads for chemoembolization, kidney, adrenal and pheochromocytoma cancer ablation, heat-deployed nanoparticle chemotherapy with thermal ablation for liver cancer, electromagnetic tracking for fusion of ultrasound to CT, MR, and PET, and fusion for biopsy and ablation.

Metrics include > 50 patents, books on radiology and interventional urology, > 600 publications (H-index of 99) including JAMA, NEJM, Nature Medicine, Nature Comm, Science, Lancet, Blood, Chest, Cancer, JCO, Clin Cancer Res, Science Translational Medicine, JNCI, JAMA Oncology, Hepatology, Medical Physics, JAMIA and Scientific Reports.

His team's research relies upon multi-disciplinary team science within multiple institutes and international public-private partnerships. His team has mentored hundreds of students, fellows, physicians, nurses, and scientists.

Teamwork and team science breed success.

See his Intramural Research Program bio page.

Harmon SA, Sanford TH, Xu S, Turkbey EB, Roth H, Xu Z, Yang D, Myronenko A, Anderson V, Amalou A, Blain M, Kassin M, Long D, Varble N, Walker SM, Bagci U, Ierardi AM, Stellato E, Plensich GG, Franceschelli G, Girlando C, Irmici G, Labella D, Hammoud D, Malayeri A, Jones E, Summers RM, Choyke PL, Xu D, Flores M, Tamura K, Obinata H, Mori H, Patella F, Cariati M, Carrafiello G, An P, Wood BJ, Turkbey B. Artificial intelligence for the detection of COVID-19 pneumonia on chest CT using multinational datasets. Nat Commun. 2020;11(1):4080.

Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, Bloom J, Gurram S, Siddiqui M, Pinsky P, Parnes H, Linehan WM, Merino M, Choyke PL, Shih JH, Turkbey B, Wood BJ, Pinto PA. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med. 2020;382(10):917-928.

Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ: Combined locoregional-immunotherapy for liver cancer. J Hepatol. 2019;70(5):999-1007.

Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390-7.

Pinto PA, Chung PH, Rastinehad AR, Baccala AA Jr, Kruecker J, Benjamin CJ, Xu S, Yan P, Kadoury S, Chua C, Locklin JK, Turkbey B, Shih JH, Gates SP, Buckner C, Bratslavsky G, Linehan WM, Glossop ND, Choyke PL, Wood BJ: Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol. 2011 Oct;186(4):1281-5